What Treatment Options Come Next for Lichen Planopilaris?
At a Glance
When lichen planopilaris keeps progressing, a dermatologist checks whether inflammation is active or hair loss reflects permanent scarring. Next steps may include changing topical treatment, adding steroid injections, or considering monitored oral medicines based on health and pregnancy plans.
In this answer
3 sections
If your lichen planopilaris (LPP) continues to progress despite your current treatment, your dermatologist will first re-evaluate your scalp to confirm that the disease is still active and that your medication has had enough time to work. The primary goal of treatment is to control symptoms and stop or slow further permanent hair loss, not necessarily to restore hair that has already been lost [1]. If a change is needed, there is no single universally established sequence of treatments. Instead, your doctor may adjust your local therapies, consider off-label systemic (oral) medications, or combine treatments based on your medical history, disease severity, and personal preferences [2].
1. Reassessing Your Condition
Before changing your treatment plan, your doctor needs to understand exactly why you are still experiencing hair loss or symptoms.
- Checking for Active Inflammation vs. Scarring: LPP causes permanent damage to hair follicles, replacing them with scar tissue [3]. Hair generally cannot regrow from a completely destroyed follicle, though partially affected follicles might recover if the inflammation is controlled [1]. Therefore, a lack of hair regrowth does not necessarily mean the disease is still active.
- Evaluating Symptoms: Itch, burning, or tenderness can indicate active disease, but they are not definitive proof on their own [4]. Symptoms could also be caused by irritation from topical treatments or another scalp condition.
- Tools for Tracking Progression: Dermatologists use trichoscopy (a magnified examination of the scalp) and standardized photographs taken over time to measure success. They look for reduced redness and scale, control of symptoms, and the absence of new bald patches [4][5]. If activity is unclear, a scalp biopsy might be recommended [6]. Because LPP can be patchy, a biopsy samples only a small area, so its results are always interpreted alongside your clinical exam and trichoscopy.
- Time and Adherence: Meaningful responses are usually measured over several months [7]. For example, medications like hydroxychloroquine may take 6 to 12 months to show their full benefit [8]. Your doctor will set up follow-up appointments to track your progress. However, if you notice rapid worsening, new expanding bald patches, or severe side effects, you should contact your doctor sooner rather than waiting for your next appointment.
2. Adjusting the Treatment Plan
If your doctor confirms that your LPP is still active, they will adjust your treatment. Many of the medications used for LPP are prescribed “off-label” (approved for other conditions but used in LPP based on medical evidence) and have different levels of supporting research [2][7]. Do not start, stop, or change the dose of any treatments or supplements without discussing it with your dermatologist.
- Optimizing Local Therapies: Your doctor might change the strength of your topical corticosteroids or try a steroid-sparing topical (a non-steroid cream, like tacrolimus, that can reduce the need for steroids) [9]. They may also add intralesional corticosteroids (steroid injections directly into the active patches) to calm stubborn inflammation [2]. Prolonged or unmonitored use of steroids can cause skin thinning, visible small blood vessels, pigment changes, or localized skin indentations (atrophy) from injections. Strength and frequency must always be prescribed and monitored by your doctor.
- Considering Systemic Medications: For moderate-to-severe or progressive LPP, systemic (oral) treatment may be considered [2]. Options with varying levels of evidence include hydroxychloroquine, methotrexate, mycophenolate mofetil, cyclosporine, or pioglitazone [7][10][11]. These are not a menu of equal choices; each carries specific risks, such as potential liver or kidney toxicity, blood pressure changes, infection risks, and pregnancy precautions [11]. For example, pioglitazone carries a risk of fluid retention (edema) and heart failure.
- Emerging and Combination Approaches: A small study provided limited, preliminary evidence that adding oral N-acetylcysteine (NAC) to topical steroids may improve results [12]. However, NAC is not a proven routine treatment; discuss it with your doctor rather than starting it on your own. For highly resistant disease, JAK inhibitors (medicines that target specific immune signals, such as tofacitinib) are sometimes considered off-label [13][14]. These require specialist supervision due to serious potential risks, including severe infections, blood clots, cardiovascular events, and an increased risk of certain malignancies.
3. Choosing the Right Path Forward
Selecting the next treatment requires a careful discussion of risks and benefits:
- Your Medical History (Comorbidities): Your doctor must consider your other health conditions, current medications, and whether you are pregnant or planning to become pregnant [2].
- Safety Monitoring: Different systemic treatments require different monitoring. Depending on the drug, this may include routine blood or liver tests, kidney monitoring, blood pressure checks, tuberculosis or hepatitis screening, or specialized exams (such as regular retinal eye exams for hydroxychloroquine) [7][11].
Important Safety Warning: Seek urgent medical care if you experience signs of a severe allergic reaction, serious infection (like high fever or severe chills), vision changes, marked weakness, or other significant, unexpected symptoms while taking these medications.
Cosmetic and Restorative Options: Once the inflammation has been completely inactive for a sustained period, you might discuss cosmetic options like scalp camouflage, wigs, or hair transplantation with a specialist. These do not treat active LPP, but they can help manage the permanent hair loss after the disease has stabilized.
Common questions in this guide
How can my dermatologist tell whether lichen planopilaris is still active?
Could hair loss continue even if my LPP inflammation is controlled?
What might my doctor try if my current LPP treatment is not enough?
What monitoring do oral lichen planopilaris medicines require?
When can I consider wigs or a hair transplant after LPP?
Which changes mean I should contact my doctor sooner or seek urgent care?
Related questions
Show more
Get notified when new evidence is published on Lichen planopilaris.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Reversible Hair Loss in Lichen Planopilaris: Regrowth With Low-Dose Naltrexone and Platelet-Rich Plasma.
Klein E, Karim M, Kim R, et al.
Journal of drugs in dermatology : JDD 2022; (21(6)):671-673 doi:10.36849/JDD.6810.
PMID: 35674753 - 2
Management of classic lichen planopilaris: The EADV task force on hair diseases position statement.
Seyed Jafari SM, Starace M, Katoulis A, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV 2026; (40(8)):1306-1317 doi:10.1111/jdv.70379.
PMID: 41848299 - 3
A Practical Approach to the Diagnosis and Management of Classic Lichen Planopilaris.
Svigos K, Yin L, Fried L, et al.
American journal of clinical dermatology 2021; (22(5)):681-692 doi:10.1007/s40257-021-00630-7.
PMID: 34347282 - 4
Assessing the correlation between trichoscopic features in lichen planopilaris and lichen planopilaris activity index.
Lajevardi V, Mahmoudi H, Moghanlou S, et al.
The Australasian journal of dermatology 2019; (60(3)):214-218 doi:10.1111/ajd.13022.
PMID: 30957880 - 5
Treatment of lichen planopilaris: methotrexate or cyclosporine a therapy?
Bulbul Baskan E, Yazici S
Cutaneous and ocular toxicology 2018; (37(2)):196-199 doi:10.1080/15569527.2017.1382503.
PMID: 28944688 - 6
Diffuse Lichen Planopilaris Masquerading as Diffuse Alopecia Areata.
Yoo LJH, Meah N, Wall D, McDonald I
Case reports in dermatology 2024; (16(1)):83-87 doi:10.1159/000538064.
PMID: 38529513 - 7
Clinical Efficacy and Safety of Methotrexate versus Hydroxychloroquine in Preventing Lichen Planopilaris Progress: A Randomized Clinical Trial.
Naeini FF, Saber M, Asilian A, Hosseini SM
International journal of preventive medicine 2017; (8()):37 doi:10.4103/ijpvm.IJPVM_156_17.
PMID: 28584619 - 8
The efficacy of antimalarial drugs in the therapy of selected forms of cicatricial alopecia.
Zbiciak-Nylec MA, Brzezińska-Wcisło L, Salwowska N
Postepy dermatologii i alergologii 2021; (38(2)):302-309 doi:10.5114/ada.2021.106208.
PMID: 34408598 - 9
Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders.
Guenther L, Lynde C, Poulin Y
Journal of cutaneous medicine and surgery 2019; (23(4_suppl)):27S-34S doi:10.1177/1203475419857668.
PMID: 31476936 - 10
Mycophenolate mofetil and lichen planopilaris: systematic review and meta-analysis.
Mostafa N, Phan K, Smith S
The Journal of dermatological treatment 2022; (33(1)):369-372 doi:10.1080/09546634.2020.1755416.
PMID: 32281437 - 11
Cyclosporine or methotrexate, which one is more promising in the treatment of lichen planopilaris?; A comparative clinical trial.
Fatemi Naeini F, Mohaghegh F, Jelvan M, et al.
International immunopharmacology 2020; (86()):106765 doi:10.1016/j.intimp.2020.106765.
PMID: 32674048 - 12
Efficacy, safety, tolerability, and satisfaction of N-acetylcysteine and pentoxifylline in lichen planopilaris patients under treatment with topical clobetasol: A triple arm blinded randomized controlled trial.
Ahmadi Kahjoogh H, Yazdanian N, Behrangi E, et al.
Dermatologic therapy 2022; (35(8)):e15639 doi:10.1111/dth.15639.
PMID: 35703373 - 13
Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients.
Goodarzi M, Dadkhahfar S, Yahyaei F, et al.
Archives of Iranian medicine 2025; (28(1)):24-28 doi:10.34172/aim.33237.
PMID: 40001326 - 14
Efficacy and safety of tofacitinib in the treatment of adults with lichen planopilaris: A randomized placebo-controlled trial.
Mahmoudi H, Daneshpajooh M, Dadkhahfar S, et al.
International immunopharmacology 2025; (162()):115129 doi:10.1016/j.intimp.2025.115129.
PMID: 40582144
This page is for informational purposes only and does not constitute medical advice. Your dermatologist should confirm whether LPP is active and guide any medication changes, monitoring, or cosmetic treatment.